Extracellular matrix remodeling in the vascular wall

Pathologie Biologie

Volumn 49, Issue 4, 2001, Pages 326-332

  Jacob, M P ^a   Badier Commander, C ^a   Fontaine, V ^a   Benazzoug, Y ^b   Feldman, L ^a   Michel, J B ^a  

^a INSERM   (France)

^b UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

Author keywords

Collagens; Elastases; Elastin; Matrix metalloproteinases; Vascular wall

Indexed keywords

ELASTASE; ELASTIN; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE;

BLOOD VESSEL WALL; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEART VENTRICLE REMODELING; HUMAN; HYDROLYSIS; INFLAMMATORY CELL; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

ANEURYSM; ANIMALS; BLOOD VESSELS; COLLAGEN; CORONARY DISEASE; ELASTIN; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; HYPERTENSION; VARICOSE VEINS;

EID: 0035021165     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(01)00151-1     Document Type: Review

References (57)

1. Connective tissue components of the blood vessel wall in health and disease
2. Collagens: Molecular biology, diseases, and potentials for therapy
3. Collagen family of proteins
4. Collagenous proteins of blood vessels
5. Enzymatic and nonenzymatic cross-linking of collagen and elastin
6. Élastine: Préparation, caractérisation, structure, biosynthèse et catabolisme
7. Extracellular matrix. 4: The elastic fiber
8. Elastin: Molecular description and function
9. Elastin is an essential determinant of arterial morphogenesis
10. Novel arterial pathology in mice and humans hemizygous for elastin
11. Genetic disorders of the elastic fiber system
12. Fibrillin: From domain structure to supramolecular assembly
13. Fibrillin-rich microfibrils of the extracellular matrix: Ultrastructure and assembly
14. Further characterization of proteins associated with elastic fiber microfibrils including the molecular cloning of MAGP-2 (MP25)
15. Fibrillines et fibrillinopathies
16. Mouse models of genetic diseases resulting from mutations in elastic fiber proteins
17. The molecular structure of cell adhesion molecules
18. Cell-matrix interactions, alterations with aging, involvement in angiogenesis
19. Matrix proteoglycans: From molecular design to cellular function
20. Les protéoglycannes. I. Molécules aux multiples fonctions … futures molécules thérapeutiques?
21. Les protéoglycannes. II. Rôles en pathologie
22. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon
23. Elastases and elastin degradation
24. Les protéases de type élastase
25. Matrix metalloproteinases
26. Matrix metalloproteinases and cardiovascular disease
27. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
28. Tissue inhibitors of metalloproteinases: Evolution, structure and function
29. Rôle des métalloprotéinases matricielles et des protéases à sérine dans la migration et l'infiltration des cellules hématopoïétiques
30. EVE and beyond, retro and prospective insights
31. Leukocyte elastase
32. Increased TIMP/MMP ratio in varicose veins: A possible explanation for extracellular matrix accumulation
33. Molecular plasticity of vascular wall during Nω-nitro-L-arginine methyl ester-induced hypertension: Modulation of proinflammatory signals
34. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study
35. Response of aortic elastin synthesis and accumulation to developing hypertension and the inhibitory effect of colchicine on this response
36. Effects of antihypertensive drug classes on regression of connective tissue components of hypertension
37. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats
38. Abnormalities of the extracellular degradation of collagen type I in essential hypertension
39. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome
40. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat
41. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery
42. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries
43. Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury
44. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis
45. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury
46. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo
47. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury
48. Acquired abdominal aortic aneurysm
49. Proteinases and inhibitors in aortic aneurysms
50. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages
51. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms
52. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta
53. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases
54. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms
55. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model
56. Prevention of aneurysm development rupture by local overexpression of plasminogen activator inhibitor-1
57. Prevention of rat cerebral aneurysm formation by inhibition of nitric oxide synthase